APP and early-onset autosomal dominant Alzheimer disease: Researchers gave APP-transgenic (tg) mouse (a mouse model of Alzheimer's disease) CNS-targeted delivery of NPY, and they discovered that NPY treatment ameliorated behavioral deficits as well as neurodegenerative pathology of APP-tg mouse and promoted the proliferation of neural precursor cells in subgranular zone of the APP-tg mouse [94].